CLINICAL_TRIALS
trial_result
· 2025-07-17
Clinical Trial Update: Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR) [Phase 3]
Summary
Arcutis Biotherapeutics completed a Phase 3 trial of ARRECTOR (topical roflumilast) for scalp psoriasis, with results posted in July 2025.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Arcutis Biotherapeutics, Inc. | Conditions: Scalp Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2025-07-17